BriaCell Therapeutics(NASDAQ) BCTXL

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)+10%
5 YearN/A
1 YearN/A
1 Month+16%
$1.06
+3.82%
+0.04Today
BriaCell Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.022026-10-12
BriaCell Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.74%USD 1.172026-10-05
1 month+16.02%USD 0.882026-09-11
3 month+9.78%USD 0.932026-07-14
Since inception+9.78%USD 0.932026-01-14

BriaCell Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.43 (Low)

Price

$1.06

Volume

12,765

Open

$1.11

Previous Close

$1.06

Daily Range

$1.01 - $1.11

52-Week Range

$0.61 - $1.40

Estimated Earnings Date

N/A

BCTXL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BriaCell Therapeutics

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer treatment. The company is advancing its Bria-IMT™ targeted immunotherapy in a pivotal Phase 3 study for metastatic breast cancer.

Products and Services
  • Bria-IMT™: A targeted immunotherapy for breast cancer
  • Combination therapies with immune checkpoint inhibitors
  • Research and development in novel cancer treatments
Growth Outlook
  • Bria-IMT™ is currently in a pivotal Phase 3 study, indicating significant progress
  • Strong focus on metastatic breast cancer, a high unmet medical need
  • Potential for partnerships with larger pharmaceutical companies
Financial Highlights
  • Market capitalization of approximately $9.9 million, reflecting investor interest
  • Stock price range between $0.88 and $1.15 over the past year
  • Recent trading volume averaging over 10,000 shares, indicating active market participation
BriaCell Therapeutics Corp. is positioned in the biotechnology sector, specifically targeting cancer treatment through innovative immunotherapy solutions. The company's flagship product, Bria-IMT™, is undergoing critical clinical trials, which could pave the way for significant advancements in cancer care. The focus on metastatic breast cancer highlights the company's commitment to addressing pressing healthcare challenges. With a relatively low market capitalization, BriaCell presents a unique opportunity for investors interested in the biotechnology field. The active trading volume suggests a growing interest in the company's potential, making it a noteworthy entity in the healthcare sector.
AI Generated • Sep 20, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

West Vancouver, BC V7T 2X1, CA

BCTXL Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

12.77K

Avg. Volume

9.11K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

BriaCell Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,803.85-0.00%
^DJIDJI
$51,687.96-0.00%
^IXICNASDAQ
$27,201.84-0.00%
BTCBitcoin
$83,069.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About BCTXL

What is the current price of BriaCell Therapeutics?

BriaCell Therapeutics is trading at $1.06 per share.

What is the 52-week range for BriaCell Therapeutics?

Over the past 52 weeks, BriaCell Therapeutics has traded between $0.61 and $1.40.

How much debt does BriaCell Therapeutics have?

BriaCell Therapeutics total debt is unavailable.

How much cash does BriaCell Therapeutics have on hand?

BriaCell Therapeutics does not have cash on hand data available.

What is BriaCell Therapeutics’s dividend yield?

BriaCell Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services